A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study1
Open Access
- 1 April 2006
- journal article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 8 (2) , 189-193
- https://doi.org/10.1215/15228517-2005-010
Abstract
The purpose of this study was to determine the response to CPT-11 administered every three weeks to adults with progressive malignant glioma, treatedKeywords
This publication has 12 references indexed in Scilit:
- Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium studyNeuro-Oncology, 2004
- Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: Final report of NABTT 97-11Neuro-Oncology, 2004
- Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimenCancer, 2003
- Irinotecan in the treatment of glioma patientsCancer, 2003
- Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastomaAnnals of Oncology, 2003
- Salvage Chemotherapy with CPT-11 for Recurrent Glioblastoma MultiformeJournal of Neuro-Oncology, 2002
- Response and progression in recurrent malignant gliomaNeuro-Oncology, 1999
- Response and progression in recurrent malignant gliomaNeuro-Oncology, 1999
- Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbitalCancer Chemotherapy and Pharmacology, 1997
- Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenograftsCancer Chemotherapy and Pharmacology, 1996